Epizyme, Inc. (NASDAQ:EPZM) – Equities researchers at SunTrust Banks raised their FY2017 EPS estimates for shares of Epizyme in a research report issued on Wednesday, according to Zacks Investment Research. SunTrust Banks analyst P. Lawson now anticipates that the biopharmaceutical company will post earnings per share of ($2.20) for the year, up from their prior forecast of ($2.34). SunTrust Banks also issued estimates for Epizyme’s Q4 2017 earnings at ($0.54) EPS, Q1 2018 earnings at ($0.55) EPS, Q2 2018 earnings at ($0.60) EPS, Q3 2018 earnings at ($0.64) EPS, Q4 2018 earnings at ($0.70) EPS, FY2018 earnings at ($2.49) EPS, FY2019 earnings at ($2.98) EPS, FY2020 earnings at ($1.39) EPS and FY2021 earnings at $0.99 EPS.
Epizyme (NASDAQ:EPZM) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.02.
A number of other equities research analysts have also recently commented on the stock. ValuEngine cut shares of Epizyme from a “hold” rating to a “sell” rating in a report on Monday, November 6th. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of Epizyme in a report on Thursday, November 2nd. Leerink Swann restated an “outperform” rating and set a $22.00 price objective (down previously from $28.00) on shares of Epizyme in a research report on Thursday, November 2nd. Royal Bank Of Canada downgraded shares of Epizyme from an “outperform” rating to a “sector perform” rating and lowered their price objective for the company from $20.00 to $16.00 in a research report on Thursday, November 2nd. Finally, Cann restated a “buy” rating and set a $26.00 price objective on shares of Epizyme in a research report on Thursday, November 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. Epizyme has a consensus rating of “Buy” and an average price target of $22.67.
Shares of Epizyme (EPZM) opened at $12.80 on Monday. Epizyme has a fifty-two week low of $9.30 and a fifty-two week high of $20.45.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Legal & General Group Plc raised its position in shares of Epizyme by 8.9% during the 1st quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock valued at $165,000 after purchasing an additional 795 shares during the period. UBS Asset Management Americas Inc. bought a new stake in shares of Epizyme during the 1st quarter valued at $175,000. BB&T Securities LLC bought a new stake in shares of Epizyme during the 2nd quarter valued at $181,000. Trexquant Investment LP bought a new stake in shares of Epizyme during the 2nd quarter valued at $184,000. Finally, SG Americas Securities LLC raised its position in shares of Epizyme by 83.3% during the 2nd quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock valued at $202,000 after purchasing an additional 6,072 shares during the period. Institutional investors and hedge funds own 70.95% of the company’s stock.
In other Epizyme news, Director David M. Mott purchased 200,000 shares of the firm’s stock in a transaction on Monday, September 18th. The shares were acquired at an average cost of $15.25 per share, for a total transaction of $3,050,000.00. Following the completion of the transaction, the director now owns 6,000 shares of the company’s stock, valued at $91,500. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the stock in a transaction that occurred on Tuesday, October 24th. The stock was sold at an average price of $16.44, for a total transaction of $246,600.00. Following the completion of the transaction, the insider now owns 23,123 shares in the company, valued at $380,142.12. The disclosure for this sale can be found here. Insiders sold 45,000 shares of company stock worth $733,950 over the last quarter. Insiders own 25.20% of the company’s stock.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.